

**BAXTER INTERNATIONAL INC.**  
**Consolidated Statements of Income**  
**Three Months Ended September 30, 2009 and 2008**  
**(unaudited)**  
**(in millions, except per share and percentage data)**

	Three Months Ended September 30,		Change
	2009	2008	
NET SALES	\$3,145	\$3,151	0%
COST OF SALES	1,513 <sup>A</sup>	1,630 <sup>A</sup>	(7%)
<b>GROSS MARGIN</b>	<b>1,632</b>	<b>1,521</b>	<b>7%</b>
<i>% of Net Sales</i>	<i>51.9%</i>	<i>48.3%</i>	<i>3.6 pts</i>
MARKETING AND ADMINISTRATIVE EXPENSES	672	681	(1%)
<i>% of Net Sales</i>	<i>21.4%</i>	<i>21.6%</i>	<i>(0.2 pts)</i>
RESEARCH AND DEVELOPMENT EXPENSES	228	230 <sup>B</sup>	(1%)
<i>% of Net Sales</i>	<i>7.2%</i>	<i>7.3%</i>	<i>(0.1 pt)</i>
NET INTEREST EXPENSE	23	20	15%
OTHER EXPENSE, NET	51 <sup>C</sup>	28 <sup>C</sup>	82%
<b>PRE-TAX INCOME</b>	<b>658</b>	<b>562</b>	<b>17%</b>
INCOME TAX EXPENSE	126	86 <sup>D</sup>	47%
<i>% of Pre-Tax Income</i>	<i>19.1%</i>	<i>15.3%</i>	<i>3.8 pts</i>
<b>NET INCOME</b>	<b>532</b>	<b>476</b>	<b>12%</b>
LESS: NONCONTROLLING INTERESTS	2	4	(50%)
<b>NET INCOME ATTRIBUTABLE TO BAXTER</b>	<b>\$530</b>	<b>\$472</b>	<b>12%</b>
<b>BASIC EPS</b>	<b>\$0.88</b>	<b>\$0.76</b>	<b>16%</b>
<b>DILUTED EPS</b>	<b>\$0.87</b>	<b>\$0.74</b>	<b>18%</b>
<b>WEIGHTED-AVERAGE NUMBER OF COMMON SHARES OUTSTANDING</b>			
Basic	605	625	
Diluted	612	638	
ADJUSTED PRE-TAX INCOME (excluding specified items)	\$739 <sup>E</sup>	\$677 <sup>E</sup>	9%
ADJUSTED NET INCOME ATTRIBUTABLE TO BAXTER (excluding specified items)	\$599 <sup>E</sup>	\$563 <sup>E</sup>	6%
ADJUSTED DILUTED EPS (excluding specified items)	\$0.98 <sup>E</sup>	\$0.88 <sup>E</sup>	11%

<sup>A</sup> Cost of sales in 2009 included a charge of \$27 million (\$22 million on an after-tax basis, or \$0.03 per diluted share) primarily related to planned retirement costs associated with the SYNDEO PCA Syringe Pump. Cost of sales in 2008 included a charge of \$72 million (\$65 million on an after-tax basis, or \$0.10 per diluted share) related to COLLEAGUE infusion pumps.

<sup>B</sup> Research and development (R&D) expenses in 2008 included an in-process R&D (IPR&D) charge of \$12 million (\$7 million on an after-tax basis, or \$0.01 per diluted share) related to the company's in-licensing agreement with Innocoll Pharmaceuticals Ltd. (Innocoll).

<sup>C</sup> Other expense, net in 2009 included an impairment charge of \$54 million (\$47 million on an after-tax basis, or \$0.08 per diluted share) associated with the discontinuation of the company's SOLOMIX drug delivery system in development. Other expense, net in 2008 included an impairment charge of \$31 million (\$19 million on an after-tax basis, or \$0.03 per diluted share) associated with the discontinuation of the CLEARSHOT pre-filled syringe program.

<sup>D</sup> Income tax expense in 2008 included a net benefit of \$15 million, or \$0.02 per diluted share, related primarily to the reversal of a valuation allowance, partially offset by tax expense associated with foreign earnings that the company planned to repatriate to the United States.

<sup>E</sup> Refer to page 9 for a description of the adjustments and a reconciliation of GAAP (generally accepted accounting principles) measures.

Note: The consolidated statements of income reflect the January 1, 2009 adoption of a new accounting standard that requires a company to present a consolidated net income measure that includes the amount attributable to noncontrolling interests (historically referred to as minority interests) for all periods presented. Prior to January 1, 2009, the noncontrolling interests' share of net income was included in other expense, net.

**BAXTER INTERNATIONAL INC.**  
**Notes to Consolidated Statements of Income**  
**Three Months Ended September 30, 2009 and 2008**  
**Description of Adjustments and Reconciliation of GAAP to Non-GAAP Measures**  
**(unaudited)**  
**(in millions, except per share and percentage data)**

**2009 description of adjustments and reconciliation of GAAP to Non-GAAP**

The company's GAAP results for the three months ended September 30, 2009 included an impairment charge associated with the discontinuation of the company's SOLOMIX drug delivery system in development and a charge primarily related to planned retirement costs associated with the SYNDEO PCA Syringe Pump, which impacted the GAAP results as follows:

	Pre-tax Income	Income Tax Expense	Net Income Attributable to Baxter	Diluted EPS
<b>GAAP</b>	<b>\$658</b>	<b>\$126</b>	<b>\$530</b>	<b>\$0.87</b>
Impairment charge	54	7	47	0.08
Infusion pump charge <sup>1</sup>	27	5	22	0.03
<b>Excluding specified items</b>	<b>\$739</b>	<b>\$138</b>	<b>\$599</b>	<b>\$0.98</b>

**Effective tax rate****18.7%**

<sup>1</sup> Included in the cost of sales line within the accompanying consolidated statements of income. Excluding this item, adjusted gross margin was \$1.66 billion and the adjusted gross margin percentage was 52.8%.

**2008 description of adjustments and reconciliation of GAAP to Non-GAAP**

The company's GAAP results for the three months ended September 30, 2008 included a charge related to COLLEAGUE infusion pumps, an impairment charge associated with the discontinuation of the CLEARSHOT pre-filled syringe program, and an IPR&D charge related to the company's in-licensing agreement with Innocoll, which impacted the GAAP results as follows:

	Pre-tax Income	Income Tax Expense	Net Income Attributable to Baxter	Diluted EPS
<b>GAAP</b>	<b>\$562</b>	<b>\$86</b>	<b>\$472</b>	<b>\$0.74</b>
Infusion pump charge <sup>1</sup>	72	7	65	0.10
Impairment charge	31	12	19	0.03
IPR&D charge <sup>2</sup>	12	5	7	0.01
<b>Excluding specified items</b>	<b>\$677</b>	<b>\$110</b>	<b>\$563</b>	<b>\$0.88</b>

**Effective tax rate****16.2%**

<sup>1</sup> Included in the cost of sales line within the accompanying consolidated statements of income. Excluding this item, adjusted gross margin was \$1.59 billion and the adjusted gross margin percentage was 50.6%.

<sup>2</sup> Included in the R&D expenses line within the accompanying consolidated statements of income. Excluding this item, adjusted R&D expenses were \$218 million, or 6.9% of net sales.

For more information on the company's use of non-GAAP financial measures in this press release, please see the company's Current Report on Form 8-K filed with the Securities and Exchange Commission on the date of this press release.

**BAXTER INTERNATIONAL INC.**  
**Consolidated Statements of Income**  
**Nine Months Ended September 30, 2009 and 2008**  
**(unaudited)**  
**(in millions, except per share and percentage data)**

	Nine Months Ended September 30,		Change
	2009	2008	
NET SALES	\$9,092	\$9,217	(1%)
COST OF SALES	4,334 <sup>A</sup>	4,689 <sup>A</sup>	(8%)
<b>GROSS MARGIN</b>	<b>4,758</b>	<b>4,528</b>	<b>5%</b>
<i>% of Net Sales</i>	<i>52.3%</i>	<i>49.1%</i>	<i>3.2 pts</i>
MARKETING AND ADMINISTRATIVE EXPENSES	1,943	2,024	(4%)
<i>% of Net Sales</i>	<i>21.4%</i>	<i>22.0%</i>	<i>(0.6 pts)</i>
RESEARCH AND DEVELOPMENT EXPENSES	671	642 <sup>B</sup>	5%
<i>% of Net Sales</i>	<i>7.4%</i>	<i>7.0%</i>	<i>0.4 pts</i>
NET INTEREST EXPENSE	73	62	18%
OTHER EXPENSE, NET	52 <sup>C</sup>	25 <sup>C</sup>	108%
<b>PRE-TAX INCOME</b>	<b>2,019</b>	<b>1,775</b>	<b>14%</b>
INCOME TAX EXPENSE	380	319 <sup>D</sup>	19%
<i>% of Pre-Tax Income</i>	<i>18.8%</i>	<i>18.0%</i>	<i>0.8 pts</i>
<b>NET INCOME</b>	<b>1,639</b>	<b>1,456</b>	<b>13%</b>
LESS: NONCONTROLLING INTERESTS	6	11	(45%)
<b>NET INCOME ATTRIBUTABLE TO BAXTER</b>	<b>\$1,633</b>	<b>\$1,445</b>	<b>13%</b>
<b>BASIC EPS</b>	<b>\$2.68</b>	<b>\$2.30</b>	<b>17%</b>
<b>DILUTED EPS</b>	<b>\$2.66</b>	<b>\$2.26</b>	<b>18%</b>
<b>WEIGHTED-AVERAGE NUMBER OF COMMON SHARES OUTSTANDING</b>			
Basic	608	628	
Diluted	615	640	
ADJUSTED PRE-TAX INCOME (excluding specified items)	\$2,100 <sup>E</sup>	\$1,943 <sup>E</sup>	8%
ADJUSTED NET INCOME ATTRIBUTABLE TO BAXTER (excluding specified items)	\$1,702 <sup>E</sup>	\$1,581 <sup>E</sup>	8%
ADJUSTED DILUTED EPS (excluding specified items)	\$2.77 <sup>E</sup>	\$2.47 <sup>E</sup>	12%

<sup>A</sup> Cost of sales in 2009 included a charge of \$27 million (\$22 million on an after-tax basis, or \$0.03 per diluted share) primarily related to planned retirement costs associated with the SYNDEO PCA Syringe Pump. Cost of sales in 2008 included charges totaling \$125 million (\$110 million on an after-tax basis, or \$0.17 per diluted share) related to COLLEAGUE infusion pumps.

<sup>B</sup> R&D expenses in 2008 included an IPR&D charge of \$12 million (\$7 million on an after-tax basis, or \$0.01 per diluted share) related to the company's in-licensing agreement with Innocoll.

<sup>C</sup> Other expense, net in 2009 included an impairment charge of \$54 million (\$47 million on an after-tax basis, or \$0.08 per diluted share) associated with the discontinuation of the company's SOLOMIX drug delivery system in development. Other expense, net in 2008 included an impairment charge of \$31 million (\$19 million on an after-tax basis, or \$0.03 per diluted share) associated with the discontinuation of the CLEARSHOT pre-filled syringe program.

<sup>D</sup> Income tax expense in 2008 included a net benefit of \$15 million, or \$0.02 per diluted share, related primarily to the reversal of a valuation allowance, partially offset by tax expense associated with foreign earnings that the company planned to repatriate to the United States.

<sup>E</sup> Refer to page 11 for a description of the adjustments and a reconciliation of GAAP measures.

Note: The consolidated statements of income reflect the January 1, 2009 adoption of a new accounting standard that requires a company to present a consolidated net income measure that includes the amount attributable to noncontrolling interests (historically referred to as minority interests) for all periods presented. Prior to January 1, 2009, the noncontrolling interests' share of net income was included in other expense, net.

**BAXTER INTERNATIONAL INC.**  
**Notes to Consolidated Statements of Income**  
**Nine Months Ended September 30, 2009 and 2008**  
**Description of Adjustments and Reconciliation of GAAP to Non-GAAP Measures**  
**(unaudited)**  
**(in millions, except per share and percentage data)**

**2009 description of adjustments and reconciliation of GAAP to Non-GAAP**

The company's GAAP results for the nine months ended September 30, 2009 included an impairment charge associated with the discontinuation of the company's SOLOMIX drug delivery system in development and a charge primarily related to planned retirement costs associated with the SYNDEO PCA Syringe Pump, which impacted the GAAP results as follows:

	Pre-tax Income	Income Tax Expense	Net Income Attributable to Baxter	Diluted EPS
<b>GAAP</b>	<b>\$2,019</b>	<b>\$380</b>	<b>\$1,633</b>	<b>\$2.66</b>
Impairment charge	54	7	47	0.08
Infusion pump charge <sup>1</sup>	27	5	22	0.03
<b>Excluding specified items</b>	<b>\$2,100</b>	<b>\$392</b>	<b>\$1,702</b>	<b>\$2.77</b>

**Effective tax rate****18.7%**

<sup>1</sup> Included in the cost of sales line within the accompanying consolidated statements of income. Excluding this item, adjusted gross margin was \$4.79 billion and the adjusted gross margin percentage was 52.6%.

**2008 description of adjustments and reconciliation of GAAP to Non-GAAP**

The company's GAAP results for the nine months ended September 30, 2008 included charges related to COLLEAGUE infusion pumps, an impairment charge associated with the discontinuation of the CLEARSHOT pre-filled syringe program, and an IPR&D charge related to the company's in-licensing agreement with Innocoll, which impacted the GAAP results as follows:

	Pre-tax Income	Income Tax Expense	Net Income Attributable to Baxter	Diluted EPS
<b>GAAP</b>	<b>\$1,775</b>	<b>\$319</b>	<b>\$1,445</b>	<b>\$2.26</b>
Infusion pump charges <sup>1</sup>	125	15	110	0.17
Impairment charge	31	12	19	0.03
IPR&D charge <sup>2</sup>	12	5	7	0.01
<b>Excluding specified items</b>	<b>\$1,943</b>	<b>\$351</b>	<b>\$1,581</b>	<b>\$2.47</b>

**Effective tax rate****18.1%**

<sup>1</sup> Included in the cost of sales line within the accompanying consolidated statements of income. Excluding this item, adjusted gross margin was \$4.65 billion and the adjusted gross margin percentage was 50.5%.

<sup>2</sup> Included in the R&D expenses line within the accompanying consolidated statements of income. Excluding this item, adjusted R&D expenses were \$630 million, or 6.8% of net sales.

For more information on the company's use of non-GAAP financial measures in this press release, please see the company's Current Report on Form 8-K filed with the Securities and Exchange Commission on the date of this press release.

**BAXTER INTERNATIONAL INC.**  
**Cash Flows from Operations and Changes in Net Debt**  
(unaudited)  
(\$ in millions)

Cash Flows from Operations (Brackets denote cash outflows)	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2009	2008	2009	2008
Net income	\$532	\$476	\$1,639	\$1,456
Adjustments				
Depreciation and amortization	164	165	466	481
Deferred income taxes	53	54	188	164
Stock compensation	32	38	106	111
Realized excess tax benefits from stock issued under employee benefit plans <sup>1</sup>	(7)	(28)	(88)	(28)
Infusion pump charges	27	72	27	125
Impairment charges	54	31	54	31
IPR&D charge	-	12	-	12
Other	21	-	35	16
Changes in balance sheet items				
Accounts and other current receivables	(50)	7	(108)	(86)
Inventories	(31)	(52)	(116)	(207)
Accounts payable and accrued liabilities	101	18	(163)	(236)
Restructuring payments	(7)	(9)	(35)	(35)
Other <sup>2</sup>	(14)	29	(82)	91
<b>Cash flows from operations</b>	<b>\$875</b>	<b>\$813</b>	<b>\$1,923</b>	<b>\$1,895</b>

Changes in Net Debt Increase (decrease)	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2009	2008	2009	2008
<b>Net debt, beginning of period</b>	<b>\$2,030</b>	<b>\$1,087</b>	<b>\$1,625</b>	<b>\$550</b>
Cash flows from operations	(875)	(813)	(1,923)	(1,895)
Capital expenditures	247	251	634	615
Dividends	157	136	475	411
Proceeds and realized excess tax benefits from stock issued under employee benefit plans	(85)	(302)	(289)	(547)
Purchases of treasury stock	100	589	966	1,522
Acquisitions of and investments in businesses and technologies	54	12	156	73
Payments related to settlements of cross-currency swaps	-	241	-	542
Other, including the effect of exchange rate changes	(30)	28	(46)	(42)
<b>(Decrease) increase in net debt</b>	<b>(432)</b>	<b>142</b>	<b>(27)</b>	<b>679</b>
<b>Net debt, September 30</b>	<b>\$1,598</b>	<b>\$1,229</b>	<b>\$1,598</b>	<b>\$1,229</b>

Key statistics, September 30:				
Days sales outstanding	58.4	55.6	58.4	55.6
Inventory turns	2.2	2.4	2.2	2.4

Selected balance sheet information:	September 30, 2009	December 31, 2008
Cash and equivalents	\$2,571	\$2,131
Accounts and other current receivables	\$2,229	\$1,980
Inventories	\$2,628	\$2,361
Accounts payable and accrued liabilities	\$3,435	\$3,241

<sup>1</sup> In accordance with GAAP, realized excess tax benefits from stock issued under employee benefit plans are presented in the statement of cash flows as an outflow within the operating section and an inflow within the financing section.

<sup>2</sup> Other cash flows from operations in the first quarter of 2009 included a planned contribution of \$100 million to the company's pension plan in the United States.

**BAXTER INTERNATIONAL INC.**  
**Net Sales**  
**Periods Ending September 30, 2009 and 2008**  
**(unaudited)**  
**(\$ in millions)**

	<b>Q3 2009</b>	<b>Q3 2008</b>	<b>% Growth @ Actual Rates</b>	<b>% Growth @ Constant Rates</b>	<b>YTD 2009</b>	<b>YTD 2008</b>	<b>% Growth @ Actual Rates</b>	<b>% Growth @ Constant Rates</b>
<b>BioScience</b>								
United States	\$675	\$617	9%	9%	\$1,968	\$1,754	12%	12%
International	710	737	(4%)	7%	2,087	2,195	(5%)	9%
<b>Total</b>	<b>\$1,385</b>	<b>\$1,354</b>	<b>2%</b>	<b>8%</b>	<b>\$4,055</b>	<b>\$3,949</b>	<b>3%</b>	<b>11%</b>
<b>Medication Delivery</b>								
United States	\$550	\$527	4%	4%	\$1,610	\$1,555	4%	4%
International	618	630	(2%)	9%	1,727	1,831	(6%)	10%
<b>Total</b>	<b>\$1,168</b>	<b>\$1,157</b>	<b>1%</b>	<b>7%</b>	<b>\$3,337</b>	<b>\$3,386</b>	<b>(1%)</b>	<b>7%</b>
<b>Renal</b>								
United States	\$97	\$95	2%	2%	\$285	\$290	(2%)	(2%)
International	479	498	(4%)	4%	1,356	1,459	(7%)	4%
<b>Total</b>	<b>\$576</b>	<b>\$593</b>	<b>(3%)</b>	<b>4%</b>	<b>\$1,641</b>	<b>\$1,749</b>	<b>(6%)</b>	<b>3%</b>
<b>Baxter excluding Transfusion Therapies</b>								
United States	\$1,322	\$1,239	7%	7%	\$3,863	\$3,599	7%	7%
International	1,807	1,865	(3%)	7%	5,170	5,485	(6%)	8%
<b>Total</b>	<b>\$3,129</b>	<b>\$3,104</b>	<b>1%</b>	<b>7%</b>	<b>\$9,033</b>	<b>\$9,084</b>	<b>(1%)</b>	<b>8%</b>
<b>Transfusion Therapies<sup>1</sup></b>								
United States	\$10	\$33	(70%)	(70%)	\$35	\$93	(62%)	(62%)
International	6	14	(57%)	(50%)	24	40	(40%)	(28%)
<b>Total</b>	<b>\$16</b>	<b>\$47</b>	<b>(66%)</b>	<b>(64%)</b>	<b>\$59</b>	<b>\$133</b>	<b>(56%)</b>	<b>(52%)</b>
<b>Baxter International Inc.</b>								
United States	\$1,332	\$1,272	5%	5%	\$3,898	\$3,692	6%	6%
International	1,813	1,879	(4%)	7%	5,194	5,525	(6%)	8%
<b>Total</b>	<b>\$3,145</b>	<b>\$3,151</b>	<b>0%</b>	<b>6%</b>	<b>\$9,092</b>	<b>\$9,217</b>	<b>(1%)</b>	<b>7%</b>

<sup>1</sup> Represents revenues associated with manufacturing, distribution and other services provided by the company to the buyer of the Transfusion Therapies (TT) business after the February 2007 divestiture.

**BAXTER INTERNATIONAL INC.**  
**Key Product Line Sales**  
**Periods Ending September 30, 2009 and 2008**  
**(unaudited)**  
**(\$ in millions)**

	Q3 2009	Q3 2008	% Growth @ Actual Rates	% Growth @ Constant Rates	YTD 2009	YTD 2008	% Growth @ Actual Rates	% Growth @ Constant Rates
<b>BioScience</b>								
Recombinants	\$528	\$516	2%	7%	\$1,494	\$1,460	2%	10%
Plasma Proteins	331	338	(2%)	7%	958	889	8%	20%
Antibody Therapy	336	307	9%	12%	1,017	908	12%	16%
Regenerative Medicine	109	104	5%	10%	317	307	3%	11%
Other <sup>1</sup>	81	89	(9%)	0%	269	385	(30%)	(21%)
<b>Total BioScience</b>	<b>\$1,385</b>	<b>\$1,354</b>	<b>2%</b>	<b>8%</b>	<b>\$4,055</b>	<b>\$3,949</b>	<b>3%</b>	<b>11%</b>
<b>Medication Delivery</b>								
IV Therapies	\$396	\$403	(2%)	6%	\$1,124	\$1,182	(5%)	6%
Global Injectables	433	403	7%	13%	1,222	1,164	5%	14%
Infusion Systems	208	235	(11%)	(8%)	612	684	(11%)	(5%)
Anesthesia	123	112	10%	14%	352	333	6%	12%
Other	8	4	100%	125%	27	23	17%	0%
<b>Total Medication Delivery</b>	<b>\$1,168</b>	<b>\$1,157</b>	<b>1%</b>	<b>7%</b>	<b>\$3,337</b>	<b>\$3,386</b>	<b>(1%)</b>	<b>7%</b>
<b>Renal</b>								
PD Therapy	\$473	\$480	(1%)	5%	\$1,347	\$1,404	(4%)	4%
HD Therapy	103	113	(9%)	(1%)	294	345	(15%)	(4%)
<b>Total Renal</b>	<b>\$576</b>	<b>\$593</b>	<b>(3%)</b>	<b>4%</b>	<b>\$1,641</b>	<b>\$1,749</b>	<b>(6%)</b>	<b>3%</b>
<b>Baxter excluding Transfusion Therapies</b>	<b>\$3,129</b>	<b>\$3,104</b>	<b>1%</b>	<b>7%</b>	<b>\$9,033</b>	<b>\$9,084</b>	<b>(1%)</b>	<b>8%</b>
<b>Transfusion Therapies <sup>2</sup></b>	<b>\$16</b>	<b>\$47</b>	<b>(66%)</b>	<b>(64%)</b>	<b>\$59</b>	<b>\$133</b>	<b>(56%)</b>	<b>(52%)</b>
<b>Total Baxter</b>	<b>\$3,145</b>	<b>\$3,151</b>	<b>0%</b>	<b>6%</b>	<b>\$9,092</b>	<b>\$9,217</b>	<b>(1%)</b>	<b>7%</b>

<sup>1</sup> Principally includes vaccines and sales of plasma to third parties.

<sup>2</sup> Represents revenues associated with manufacturing, distribution and other services provided by the company to the buyer of the TT business after the February 2007 divestiture.

**BAXTER INTERNATIONAL INC.**  
**Key Product Line Sales by US and International**  
**Three-Month Periods Ending September 30, 2009 and 2008**  
**(unaudited)**  
**(\$ in millions)**

	Q3 2009			Q3 2008			% Growth		
	US	International	Total	US	International	Total	US	International	Total
<b>BioScience</b>									
Recombinants	\$237	\$291	\$528	\$220	\$296	\$516	8%	(2%)	2%
Plasma Proteins	126	205	331	108	230	338	17%	(11%)	(2%)
Antibody Therapy	239	97	336	217	90	307	10%	8%	9%
Regenerative Medicine	62	47	109	55	49	104	13%	(4%)	5%
Other <sup>1</sup>	11	70	81	17	72	89	(35%)	(3%)	(9%)
<b>Total BioScience</b>	<b>\$675</b>	<b>\$710</b>	<b>\$1,385</b>	<b>\$617</b>	<b>\$737</b>	<b>\$1,354</b>	<b>9%</b>	<b>(4%)</b>	<b>2%</b>
<b>Medication Delivery</b>									
IV Therapies	\$122	\$274	\$396	\$115	\$288	\$403	6%	(5%)	(2%)
Global Injectables	228	205	433	209	194	403	9%	6%	7%
Infusion Systems	118	90	208	133	102	235	(11%)	(12%)	(11%)
Anesthesia	81	42	123	70	42	112	16%	0%	10%
Other	1	7	8	0	4	4	100%	75%	100%
<b>Total Medication Delivery</b>	<b>\$550</b>	<b>\$618</b>	<b>\$1,168</b>	<b>\$527</b>	<b>\$630</b>	<b>\$1,157</b>	<b>4%</b>	<b>(2%)</b>	<b>1%</b>
<b>Renal</b>									
PD Therapy	\$76	\$397	\$473	\$73	\$407	\$480	4%	(2%)	(1%)
HD Therapy	21	82	103	22	91	113	(5%)	(10%)	(9%)
<b>Total Renal</b>	<b>\$97</b>	<b>\$479</b>	<b>\$576</b>	<b>\$95</b>	<b>\$498</b>	<b>\$593</b>	<b>2%</b>	<b>(4%)</b>	<b>(3%)</b>
<b>Baxter excluding Transfusion Therapies</b>	<b>\$1,322</b>	<b>\$1,807</b>	<b>\$3,129</b>	<b>\$1,239</b>	<b>\$1,865</b>	<b>\$3,104</b>	<b>7%</b>	<b>(3%)</b>	<b>1%</b>
<b>Transfusion Therapies<sup>2</sup></b>	<b>\$10</b>	<b>\$6</b>	<b>\$16</b>	<b>\$33</b>	<b>\$14</b>	<b>\$47</b>	<b>(70%)</b>	<b>(57%)</b>	<b>(66%)</b>
<b>Total Baxter</b>	<b>\$1,332</b>	<b>\$1,813</b>	<b>\$3,145</b>	<b>\$1,272</b>	<b>\$1,879</b>	<b>\$3,151</b>	<b>5%</b>	<b>(4%)</b>	<b>0%</b>

<sup>1</sup> Principally includes vaccines and sales of plasma to third parties.

<sup>2</sup> Represents revenues associated with manufacturing, distribution and other services provided by the company to the buyer of the TT business after the February 2007 divestiture.